Testing a new drug to shrink hidden HIV in people with suppressed virus
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests whether adding a new anti-HIV drug called lenacapavir to your regular HIV treatment can shrink the hidden reservoir of virus in your body. This could be a step toward a cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to have HIV and be on antiretroviral therapy (ART) for at least 3 years with most viral load tests showing undetectable levels (below 40 copies/mL). Occasional small blips might be allowed.
- Your CD4 count (a measure of immune health) must be above 200.
- You must have a larger-than-usual amount of hidden HIV in your cells (the 'reservoir'), which will be checked with a blood test.
- You should not have active hepatitis B or C, and you must not be pregnant or breastfeeding.
- You cannot be taking certain medications that might interfere with the study drug, such as some antibiotics, antifungals, HIV meds, or herbal supplements (St. John's wort).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This trial tests a new type of medicine that aims to wake up HIV hiding in your body's cells by targeting a viral protein called Tat. The goal is to help find a way to clear the virus completely.
This study tests whether giving two experimental drugs together can help your immune system find and destroy hidden HIV cells. It aims to see if this approach can reduce the amount of virus in your body even while you're on your regular HIV medications.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.